RBC Capital Upgrades Incyte (INCY) to Outperform

Go back to RBC Capital Upgrades Incyte (INCY) to Outperform

Incyte (INCY) PT Lowered to $120 at Oppenheimer; Remains Sidelined

January 2, 2018 6:52 AM EST

Oppenheimer lowered its price target on Incyte (NASDAQ: INCY) to $120.00 (from $135.00) while maintaining a Perform rating. Analyst Jay Olson believes that a significant contributor to INCY market cap loss since ESMO was reduced confidence in epacadostat at least partially related to significantly lower... More